ArticleEuropean journal of haematology2026
Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On-Demand Recombinant von Willebrand Factor in the United Kingdom.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On-Demand Recombinant von Willebrand Factor in the United Kingdom.European journal of haematology · 2026Article
- Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom.European journal of haematology · 2026Article
- Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application.Therapeutic advances in hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesWe describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom.
methodsRetrospective chart review of adults (≥ 18 years) with congenital VWD receiving first-time rVWF for the on-demand treatment of spontaneous/traumatic bleeds, or the prevention/treatment of surgical bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD-related HCRU data associated with the on-demand treatment of all recorded bleeds were collected at first (index) treatment, for 12 months pre-index and 3-12 months post-index.
resultsTwelve patients (91.7% female and White/Caucasian, mean age 34.2 years) were treated on demand with rVWF at index: bleed resolution was achieved for all bleeds with limited requirement for additional treatments, no treatment switches, and no complications reported. Physician-rated treatment satisfaction was 'excellent' (82.6%) or 'good' (17.4%) for all recorded on-demand rVWF-treated bleeds (n = 23). Patients receiving any on-demand treatment required an inpatient admission and ≥ 1 outpatient visit in 33.7% and 66.7% of cases, respectively.
conclusionsResults support the effectiveness and safety profile of on-demand rVWF treatment for spontaneous/traumatic bleeds in adults with VWD, adding to the growing body of evidence for rVWF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.